MX367473B - Composiciones de fosfato de calcio sustituido con magnesio amorfo, y sus usos. - Google Patents

Composiciones de fosfato de calcio sustituido con magnesio amorfo, y sus usos.

Info

Publication number
MX367473B
MX367473B MX2016005415A MX2016005415A MX367473B MX 367473 B MX367473 B MX 367473B MX 2016005415 A MX2016005415 A MX 2016005415A MX 2016005415 A MX2016005415 A MX 2016005415A MX 367473 B MX367473 B MX 367473B
Authority
MX
Mexico
Prior art keywords
amorphous magnesium
substituted calcium
calcium phosphate
phosphate compositions
cargo
Prior art date
Application number
MX2016005415A
Other languages
English (en)
Other versions
MX2016005415A (es
Inventor
Joseph Powell Jonathan
Jorge Rodrigues Faria Nuno
PELE Laetitia
HEWITT Rachel
THOMAS-MCKAY Emma
Original Assignee
Res & Innovation Uk
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Res & Innovation Uk filed Critical Res & Innovation Uk
Publication of MX2016005415A publication Critical patent/MX2016005415A/es
Publication of MX367473B publication Critical patent/MX367473B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/501—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0002—General or multifunctional contrast agents, e.g. chelated agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0063—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres
    • A61K49/0069—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres the agent being in a particular physical galenical form
    • A61K49/0089—Particulate, powder, adsorbate, bead, sphere
    • A61K49/0091—Microparticle, microcapsule, microbubble, microsphere, microbead, i.e. having a size or diameter higher or equal to 1 micrometer
    • A61K49/0093—Nanoparticle, nanocapsule, nanobubble, nanosphere, nanobead, i.e. having a size or diameter smaller than 1 micrometer, e.g. polymeric nanoparticle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5115—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C01—INORGANIC CHEMISTRY
    • C01B—NON-METALLIC ELEMENTS; COMPOUNDS THEREOF; METALLOIDS OR COMPOUNDS THEREOF NOT COVERED BY SUBCLASS C01C
    • C01B25/00—Phosphorus; Compounds thereof
    • C01B25/16—Oxyacids of phosphorus; Salts thereof
    • C01B25/26—Phosphates
    • C01B25/32—Phosphates of magnesium, calcium, strontium, or barium
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/585—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with a particulate label, e.g. coloured latex
    • G01N33/587—Nanoparticles

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Nanotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Hematology (AREA)
  • Optics & Photonics (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Polymers & Plastics (AREA)
  • Nutrition Science (AREA)
  • Pulmonology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)

Abstract

Se describen las composiciones de fosfato de calcio sustituido con magnesio amorfo, y sus usos médicos, en particular para usarse en la distribución de materiales de carga, tales como moléculas de carga o nanopartículas de carga contenidas en poros de fosfato de calcio sustituido con magnesio amorfo hacia las células del sistema inmunitario, por ejemplo como procedimientos terapéuticos para el tratamiento de trastornos inflamatorios del intestino, y en particular la enfermedad de Crohn, trastornos autoinmunitarios, alergia y para vacunación terapéutica.
MX2016005415A 2013-11-05 2014-11-05 Composiciones de fosfato de calcio sustituido con magnesio amorfo, y sus usos. MX367473B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1319548.2A GB201319548D0 (en) 2013-11-05 2013-11-05 Amorphous magnesium-substituted calcium phosphate compositions and their uses
PCT/GB2014/053291 WO2015067939A1 (en) 2013-11-05 2014-11-05 Amorphous magnesium-substituted calcium phosphate compositions and their uses

Publications (2)

Publication Number Publication Date
MX2016005415A MX2016005415A (es) 2017-03-01
MX367473B true MX367473B (es) 2019-08-23

Family

ID=49767709

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016005415A MX367473B (es) 2013-11-05 2014-11-05 Composiciones de fosfato de calcio sustituido con magnesio amorfo, y sus usos.

Country Status (16)

Country Link
US (1) US10596122B2 (es)
EP (1) EP3065715B1 (es)
JP (2) JP2016537408A (es)
KR (1) KR20160079060A (es)
CN (1) CN105722504A (es)
AU (1) AU2014345334B2 (es)
BR (1) BR112016009809A2 (es)
CA (1) CA2929123A1 (es)
EA (1) EA201690659A1 (es)
ES (1) ES2761559T3 (es)
GB (1) GB201319548D0 (es)
IL (1) IL245380B (es)
MX (1) MX367473B (es)
SG (2) SG10201803562YA (es)
WO (1) WO2015067939A1 (es)
ZA (1) ZA201602906B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201319548D0 (en) 2013-11-05 2013-12-18 Medical Res Council Amorphous magnesium-substituted calcium phosphate compositions and their uses
FR3021045B1 (fr) * 2014-05-16 2020-02-21 Solvay Sa Procede de production d'un reactif phosphocalcique, reactif obtenu et son utilisation
KR101893110B1 (ko) * 2016-07-27 2018-08-31 삼일제약 주식회사 비페닐디메틸디카르복실레이트 및 마늘유를 포함하는 제제
CN110520534A (zh) * 2016-11-09 2019-11-29 恩根尼公司 程序性死亡配体1的肠表达
WO2018198296A1 (ja) * 2017-04-27 2018-11-01 ブレイニー株式会社 ハイドロキシアパタイト、化粧品及び食品、並びにその製造方法
CN111417459B (zh) * 2019-07-05 2020-12-29 广州中大医疗器械有限公司 一种可载药微球及其制备方法
WO2021086252A1 (en) 2019-10-30 2021-05-06 Psilox Ab Stabilized amorphous calcium magnesium phosphate particle compositions
CN116768175B (zh) * 2023-07-01 2025-12-19 常州市第二人民医院 高稳定性生物活性无定形磷酸钙镁的制备方法及应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5443832A (en) * 1990-04-16 1995-08-22 Institut Swisse De Recherches Experimentales Sur Le Cancer Hydroxyapatite-antigen conjugates and methods for generating a poly-Ig immune response
US6541037B1 (en) * 1995-05-19 2003-04-01 Etex Corporation Delivery vehicle
WO2006109635A1 (ja) * 2005-04-06 2006-10-19 Kabushiki Kaisha Sangi 腸管吸収用抗腫瘍剤
CN101557720B (zh) * 2006-12-12 2013-05-29 弗门尼舍有限公司 具有无定形金属盐作为载体的活性成分递送系统
CN102014880A (zh) * 2008-05-01 2011-04-13 Nod药物公司 治疗性磷酸钙颗粒及其制备和使用方法
GB201319548D0 (en) 2013-11-05 2013-12-18 Medical Res Council Amorphous magnesium-substituted calcium phosphate compositions and their uses

Also Published As

Publication number Publication date
MX2016005415A (es) 2017-03-01
GB201319548D0 (en) 2013-12-18
ES2761559T3 (es) 2020-05-20
SG11201603261PA (en) 2016-05-30
US10596122B2 (en) 2020-03-24
SG10201803562YA (en) 2018-06-28
CN105722504A (zh) 2016-06-29
EA201690659A1 (ru) 2016-10-31
WO2015067939A1 (en) 2015-05-14
AU2014345334A1 (en) 2016-05-19
EP3065715A1 (en) 2016-09-14
US20160235683A1 (en) 2016-08-18
AU2014345334B2 (en) 2019-10-31
EP3065715B1 (en) 2019-10-02
CA2929123A1 (en) 2015-05-14
JP2016537408A (ja) 2016-12-01
KR20160079060A (ko) 2016-07-05
IL245380A0 (en) 2016-06-30
JP2020073467A (ja) 2020-05-14
ZA201602906B (en) 2019-09-25
IL245380B (en) 2019-02-28
BR112016009809A2 (pt) 2017-12-05

Similar Documents

Publication Publication Date Title
MX367473B (es) Composiciones de fosfato de calcio sustituido con magnesio amorfo, y sus usos.
SG10201808102WA (en) Bicyclic heterocycle compounds and their uses in therapy
PH12014501815A1 (en) Purinone compounds as kinase inhibitors
MX362725B (es) Bacterias probioticas.
EA201800199A1 (ru) Применение akkermansia muciniphila для лечения метаболических расстройств, увеличения расхода энергии и снижения веса, композиции, лекарственное стедство
PH12017501583A1 (en) Novel proteins specific for cd137
WO2013169864A3 (en) TETRAHYDRO[1,8]NAPHTHYRIDINE SULFONAMIDE AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORƴ AND THE TREATMENT OF DISEASE
TN2015000174A1 (en) Pyrrolopyrimidine compounds as kinase inhibitors
SG10201803331PA (en) Pyrrolo[3,2-d]pyrimidine derivatives for the treatment of viral infections and other diseases
PH12016500575A1 (en) Inhibitors of bruton`s tyrosine kinase
MX365114B (es) Derivados pirrolo[3,2-d]pirimidinicos para el tratamiento de infecciones viricas y otras enfermedades.
IL257057A (en) Biologically active peptides derived from soy for use in preparations and methods for wound healing, tissue engineering and regenerative medicine
WO2013186777A3 (en) Use of blocking agents of bone morphogenie protein (bmp) signaling for the treatment of neuroinflammatory and neurodegenerative diseases
MX2013011421A (es) Derivados de pirazolo-pirimidina.
MX2022008842A (es) Proteinas para el tratamiento de trastornos de la funcion de la barrera epitelial.
MX341020B (es) Peptidos derivados de lactoferrina humana y su uso.
UY33219A (es) Cetoenoles cíclicos para terapias
PH12016502233A1 (en) (s)-pirlindole or its pharmaceutically acceptable salts for use in medicine
MX2016005976A (es) Formulaciones de tripeptido liofilizado estables en almacenamiento.
PH12017500018B1 (en) Myo-inositol and probiotics, and their use
MX2015014905A (es) Compuestos de pirazino - [1,2-a] indol, su preparacion y su uso en medicamentos.
PH12015502420A1 (en) PYRAZINO[1,2-a]INDOLE COMPOUNDS, THEIR PREPARATION AND USE IN MEDICAMENTS
EP2902024A4 (en) A SYNERGISTIC COMPOSITION OF NITAZOXANIDE AND MEANDAZOL, METHOD FOR THE PRODUCTION THEREOF AND USE OF THIS COMPOSITION FOR THE TREATMENT OF HUMAN PARASITES
WO2014143763A3 (en) Angiogenic compositions for wounds, articular joints and graft materials
IL235095A0 (en) Intrauterine application of 18-methyl-15 in cell, 16 in cell-methylene-19-nor-20-spirox-4-en-3-one systems, intrauterine systems containing 18-methyl-15 in cell, 16 in cell-methylene- 19-nor-20-spirox-4-en-3-one and their use in contraception and gynecological treatment

Legal Events

Date Code Title Description
GB Transfer or rights

Owner name: UNITED KINGDOM RESEARCH AND INNOVATION

FG Grant or registration